Tonix is investing in domestic, in-house, research & development to accelerate development timelines and improve the ability to respond to pandemics.

Research and Development Center

Frederick, Maryland

Tonix’s 48,000 square foot Research and Development Center (RDC) in Frederick, Maryland supports its expanding infectious disease pipeline by accelerating internal discovery and development of vaccines and antiviral drugs against COVID-19, its variants, and other infectious diseases. The facility also houses research advancing CNS and immunology drugs. Acquired in October 2021, the main building is constructed as a Biosafety Level (BSL)-2 facility, with some areas designated BSL-3 so that research may be conducted on live SARS-CoV-2 and other pathogens. At full capacity, the RDC can employ 80-100 scientists and technical support staff.